Trial Profile
A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Amcenestrant (Primary) ; Everolimus (Primary) ; Palbociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms AMEERA-1
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 11 Feb 2024 This study has been discontinued in Portugal, according to European Clinical Trials Database record.
- 04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 24 Jan 2023 Planned End Date changed from 29 Dec 2023 to 29 Dec 2027.